← Browse by Condition
Medical Condition

allogeneic hematopoietic cell transplant

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for allogeneic hematopoietic cell transplant sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — allogeneic hematopoietic cell transplant Clinical Trials

How many clinical trials are currently recruiting for allogeneic hematopoietic cell transplant?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for allogeneic hematopoietic cell transplant, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for allogeneic hematopoietic cell transplant?
allogeneic hematopoietic cell transplant research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a allogeneic hematopoietic cell transplant clinical trial?
Eligibility criteria for allogeneic hematopoietic cell transplant trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
1
Top Sponsors
Pierre Fabre Medicament 1 trial

Recruiting Clinical Trials

NCT03394365 Phase 3
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Enrollment
115 pts
Location
United States, Austr...
Sponsor
Pierre Fabre Medicament
View Trial →

Related Conditions

epstein barr virus associated post transplant lymphoproliferative disease ebv ptld (1) solid organ transplant complications (1) lymphoproliferative disorders (1) stem cell transplant complications (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology